Introduction to atarax (hydroxyzine)
Atarax is a brand name for hydroxyzine, a first-generation antihistamine medication that belongs to the piperazine class of compounds. Originally developed in the 1950s, hydroxyzine has been used for decades to treat various conditions including anxiety, allergic reactions, nausea, and insomnia. Unlike many newer antihistamines, hydroxyzine has sedative properties that make it particularly useful for patients who need relief from anxiety accompanied by agitation or difficulty sleeping. Patients seeking affordable access to this versatile medication can find it through a Happy Family Store, which offers competitive pricing on many pharmaceutical products.
Hydroxyzine works primarily by blocking histamine H1 receptors in the body, but it also has significant anticholinergic, antiemetic, and anxiolytic properties. This broad pharmacological profile makes Atarax useful across multiple medical specialties, including dermatology, psychiatry, allergy and immunology, and anesthesiology. The medication is available in oral tablet form, oral syrup, and intramuscular injection, providing flexibility in administration depending on patient needs and clinical circumstances.
The sedative properties of hydroxyzine distinguish it from second-generation antihistamines like cetirizine and loratadine, which are specifically designed to be non-sedating. While sedation may be considered a side effect in some contexts, it is therapeutically beneficial for patients with anxiety disorders, preoperative anxiety, and pruritus (itching) that interferes with sleep. The onset of action for oral hydroxyzine is typically within 15 to 30 minutes, with peak effects occurring at about 2 hours following administration.
Medical uses and indications
Atarax is FDA-approved for three primary indications: management of anxiety, treatment of pruritus (itching), and as a preoperative sedative. However, clinical experience has demonstrated its effectiveness for numerous off-label uses as well. In psychiatric practice, hydroxyzine is commonly prescribed for generalized anxiety disorder (GAD), particularly in patients who cannot tolerate benzodiazepines or selective serotonin reuptake inhibitors (SSRIs), or those who need rapid relief of acute anxiety symptoms.
The anxiolytic (anxiety-reducing) effect of hydroxyzine is believed to result from its activity at multiple receptor sites, including histamine H1 receptors, serotonin receptors, and possibly gamma-aminobutyric acid (GABA) receptors. Unlike benzodiazepines, which carry a significant risk of dependence and tolerance, hydroxyzine has very low abuse potential and can be used safely for longer periods without the need for dose escalation. This makes it an attractive option for patients with mild to moderate anxiety who require ongoing treatment.
In dermatology, Atarax is a first-line treatment for urticaria (hives) and other pruritic conditions. The antipruritic effect of hydroxyzine is mediated primarily through H1 receptor blockade in the skin, but the medication’s sedative properties also contribute to symptom relief by helping patients sleep through the urge to scratch. Chronic pruritus associated with conditions such as atopic dermatitis, eczema, contact dermatitis, and systemic diseases including liver disease and kidney failure may respond well to hydroxyzine therapy.
Allergic conditions treated with Atarax include seasonal and perennial allergic rhinitis, allergic conjunctivitis, and allergic dermatoses. By blocking the effects of histamine released from mast cells during allergic reactions, hydroxyzine reduces sneezing, runny nose, itchy eyes, and skin rashes. For acute allergic reactions, intramuscular hydroxyzine may be used in emergency settings to provide rapid symptom relief, often in combination with epinephrine and corticosteroids.
As a preoperative sedative, Atarax is used to reduce anxiety and produce calmness before surgical procedures. Its antiemetic properties also help prevent postoperative nausea and vomiting, and its sedative effects complement the action of anesthetic agents. The medication’s ability to reduce the requirement for opioid analgesics postoperatively is an additional benefit in surgical settings.
Nausea and vomiting associated with various causes, including motion sickness, gastroenteritis, and postoperative recovery, may be treated with hydroxyzine. The antiemetic effect is mediated through blockade of histamine H1 receptors in the vomiting center of the brainstem and through anticholinergic effects that reduce gastrointestinal motility and secretions.
Insomnia, particularly when associated with anxiety or pruritus, may be effectively treated with Atarax. The sedative properties of hydroxyzine promote sleep onset and maintenance, though the medication’s duration of action may lead to morning drowsiness in some patients. Lower doses are generally recommended when hydroxyzine is used specifically for sleep, and the medication should be used as part of a comprehensive approach to sleep hygiene.
Dosage forms and strengths
Atarax (hydroxyzine hydrochloride) is available in several oral formulations. Tablets are typically manufactured in 10 mg, 25 mg, and 50 mg strengths, allowing for flexible dosing based on patient age, weight, and the condition being treated. The 25 mg tablet is the most commonly prescribed strength for adults with anxiety or pruritus, with dosing ranging from 25 mg three or four times daily to 50 mg four times daily for more severe symptoms.
Hydroxyzine oral syrup is available on prescription and contains 10 mg per 5 mL (teaspoon), making it suitable for pediatric patients and adults who have difficulty swallowing tablets. The syrup formulation allows for precise dose adjustment based on body weight, which is particularly important for children. The syrup has a pleasant flavor that improves compliance in pediatric patients.
Intramuscular injection of hydroxyzine is used in hospital settings for acute anxiety, severe allergic reactions, and as a preoperative sedative. The injectable formulation provides rapid onset of action and is useful when oral administration is not feasible due to nausea, vomiting, or patient inability to swallow.
The recommended dosage for anxiety in adults typically starts at 50 mg to 100 mg four times daily, with adjustment based on clinical response and tolerability. For pruritus, the usual adult dose ranges from 25 mg three to four times daily. Pediatric dosing for both conditions is based on body weight, typically 0.5 mg to 1 mg per pound (1 mg to 2 mg per kilogram) per day, divided into multiple doses.
Pharmacokinetics
Hydroxyzine is well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations occurring approximately 2 hours after dosing. The medication undergoes extensive first-pass metabolism in the liver, primarily through the CYP3A4 and CYP2D6 enzyme systems, and its major active metabolite is cetirizine, which is itself a potent second-generation antihistamine marketed as Zyrtec.
The presence of cetirizine as an active metabolite explains why some effects of hydroxyzine persist longer than would be expected based on the parent compound’s half-life. The elimination half-life of hydroxyzine in adults ranges from 3 to 7 hours in younger adults but may be extended to 20 hours or more in elderly patients and those with hepatic impairment. Consequently, dosing adjustments are often necessary for geriatric patients and those with liver disease.
Hydroxyzine is widely distributed throughout the body, including penetration into the central nervous system, which accounts for its sedative and anxiolytic effects. The medication crosses the placental barrier and is excreted in breast milk, which has implications for use during pregnancy and breastfeeding.
Mechanism of action
The primary mechanism of action of hydroxyzine is competitive antagonism of histamine at H1 receptor sites. Histamine is a biogenic amine that is released from mast cells and basophils during allergic and inflammatory responses. When histamine binds to H1 receptors on blood vessels, smooth muscle, and nerve endings, it produces vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings leading to itching and pain.
By blocking H1 receptors, hydroxyzine prevents histamine from exerting these effects, resulting in reduced capillary permeability, decreased wheal and flare responses, and relief from itching and other allergic symptoms. The medication’s high affinity for H1 receptors and good penetration into the central nervous system contribute to its effectiveness as both an antihistamine and a sedative.
Beyond its antihistamine activity, hydroxyzine has demonstrated antagonistic effects at serotonin 5-HT2A receptors, dopamine D2 receptors, and alpha-adrenergic receptors. The serotonergic activity is thought to contribute to the medication’s anxiolytic effects, as 5-HT2A receptor blockade has been associated with reduced anxiety in both animal models and clinical studies. Some researchers have also proposed that hydroxyzine may modulate GABAergic transmission, though this mechanism is less well established.
The anticholinergic properties of hydroxyzine result from blockade of muscarinic acetylcholine receptors. This contributes to the medication’s antiemetic effects and its utility in reducing gastrointestinal secretions, but it is also responsible for many of the side effects associated with hydroxyzine, including dry mouth, blurred vision, constipation, and urinary retention.
Side effects and adverse reactions
The most common side effect of Atarax is sedation or drowsiness, which occurs in a significant proportion of patients, particularly at higher doses. While this effect can be therapeutically beneficial for patients with anxiety or insomnia, it may be problematic for individuals who need to remain alert for activities such as driving or operating machinery. Tolerance to the sedative effects often develops over several days to weeks of continued therapy.
Anticholinergic side effects are frequently reported and include dry mouth, blurred vision, constipation, difficulty urinating, and decreased sweating. These effects are dose-dependent and may be more pronounced in elderly patients, who are also more susceptible to confusion, cognitive impairment, and falls as a result of hydroxyzine’s anticholinergic activity.
Gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation may occur, though they are generally mild and self-limiting. Taking the medication with food may help reduce gastrointestinal discomfort. Appetite changes, both increased and decreased, have been reported in some patients.
Neurological side effects beyond sedation include headache, dizziness, weakness, and ataxia (impaired coordination). Paradoxical reactions characterized by increased anxiety, agitation, insomnia, or even seizures have been reported, particularly in pediatric patients and the elderly. Tremor and involuntary muscle movements are rare but have been documented.
Cardiovascular effects are uncommon at therapeutic doses but may include tachycardia (rapid heart rate), palpitations, and hypotension. Hydroxyzine can prolong the QT interval on electrocardiogram, particularly at high doses or when combined with other medications that affect cardiac conduction. Patients with pre-existing heart conditions should use this medication with caution.
Allergic reactions to hydroxyzine itself are rare but can include rash, urticaria, angioedema, and anaphylaxis. Cross-sensitivity with other piperazine derivatives such as cetirizine and levocetirizine may occur in susceptible individuals. Patients with a history of allergic reactions to similar medications should avoid hydroxyzine.
Respiratory side effects are uncommon but may include thickening of bronchial secretions, which can be problematic for patients with asthma or chronic obstructive pulmonary disease (COPD). The anticholinergic effects can reduce airway secretions, potentially exacerbating respiratory conditions in susceptible individuals.
Drug interactions
Atarax can interact with numerous other medications, and careful review of a patient’s complete medication list is essential before initiating therapy. Central nervous system depressants including alcohol, benzodiazepines, opioid analgesics, barbiturates, and other sedative-hypnotics can have additive sedative effects when combined with hydroxyzine, increasing the risk of excessive sedation, respiratory depression, and impaired cognitive and motor function.
Anticholinergic medications such as tricyclic antidepressants, antispasmodics, and antimuscarinic agents used for overactive bladder can have additive anticholinergic effects when combined with hydroxyzine, increasing the risk of dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment in elderly patients.
Monoamine oxidase inhibitors (MAOIs) can prolong and intensify the anticholinergic effects of hydroxyzine. Although this combination is not absolutely contraindicated, it should be used with caution and close monitoring. Similarly, other antihistamines, including both prescription and over-the-counter products, can have additive effects when combined with hydroxyzine and should be used together only under medical supervision.
Medications that inhibit CYP3A4 or CYP2D6, such as ketoconazole, itraconazole, erythromycin, clarithromycin, fluoxetine, paroxetine, and certain protease inhibitors, may reduce the metabolism of hydroxyzine and increase its plasma concentration, potentially leading to enhanced effects and increased risk of side effects. Conversely, CYP3A4 inducers such as rifampin and carbamazepine may decrease hydroxyzine levels and reduce its effectiveness.
QT-prolonging medications including certain antiarrhythmics, antipsychotics, antibiotics, and antidepressants should be used with caution in combination with hydroxyzine due to the potential for additive QT prolongation and increased risk of serious cardiac arrhythmias such as torsade de pointes. An electrocardiogram should be considered before initiating therapy in patients at risk for QT prolongation.
Contraindications and precautions
Atarax is contraindicated in patients with known hypersensitivity to hydroxyzine or any piperazine derivative, including cetirizine and levocetirizine. The medication should not be used in patients with porphyria, as it may precipitate acute attacks. Early pregnancy is a relative contraindication, as hydroxyzine has been associated with an increased risk of congenital abnormalities in some animal studies.
Patients with narrow-angle glaucoma should use hydroxyzine with caution due to its anticholinergic effects, which can increase intraocular pressure. Similarly, patients with prostatic hyperplasia or urinary retention may experience worsening of their symptoms due to the medication’s effects on bladder function. Patients with gastrointestinal obstruction or paralytic ileus should avoid hydroxyzine due to its anticholinergic effects on gastrointestinal motility.
Patients with hepatic impairment require dose reduction and careful monitoring, as hydroxyzine is primarily metabolized in the liver. Those with severe liver disease may experience prolonged half-life and increased risk of adverse effects. Similarly, patients with renal impairment, particularly those with creatinine clearance below 50 mL/min, may require dose adjustment to prevent accumulation of the medication and its active metabolites.
Elderly patients are generally more sensitive to the effects of hydroxyzine, particularly the anticholinergic and sedative effects. The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults lists hydroxyzine as a medication to avoid in elderly patients due to its strong anticholinergic properties and increased risk of confusion, falls, and cognitive decline, though short-term use may be appropriate in some circumstances.
Use in special populations
Pregnancy: Hydroxyzine is classified as FDA Pregnancy Category C, indicating that animal studies have shown adverse effects on the fetus but adequate human studies are lacking. The medication should be used during pregnancy only if the potential benefit clearly outweighs the potential risk. Some studies have suggested an association between first-trimester exposure to hydroxyzine and an increased risk of congenital malformations, particularly cleft palate.
Breastfeeding: Hydroxyzine is excreted in breast milk, and the American Academy of Pediatrics considers it compatible with breastfeeding, though caution is advised. The medication may cause sedation or irritability in nursing infants, and the lowest effective dose should be used for the shortest duration necessary. Alternative antihistamines with less sedation and lower milk concentrations may be preferred during lactation.
Pediatric use: Atarax is approved for use in children for the treatment of pruritus and as a preoperative sedative. Pediatric dosing is based on body weight, and the medication should be used with caution in very young children, particularly neonates, who may be more susceptible to the anticholinergic and sedative effects. Paradoxical reactions including agitation and hyperactivity are more common in children than adults.
Geriatric use: As previously noted, elderly patients are at increased risk for adverse effects from hydroxyzine, particularly sedation, dizziness, confusion, and anticholinergic effects. Lower starting doses and careful monitoring are essential in this population. Non-sedating antihistamines are generally preferred for allergic conditions in elderly patients when sedation is not therapeutically desired.
Overdose and toxicity
Hydroxyzine overdose can occur with intentional or accidental ingestion of excessive amounts. Symptoms of overdose include excessive sedation, dizziness, confusion, hypotension, and anticholinergic effects such as dry mouth, dilated pupils, flushed skin, and urinary retention. In severe cases, overdose can lead to seizures, cardiac arrhythmias, respiratory depression, and coma.
The management of hydroxyzine overdose is primarily supportive, with attention to maintaining airway protection, adequate ventilation, and cardiovascular stability. Activated charcoal may be administered if the ingestion occurred within one hour, provided the patient’s airway is protected. Physostigmine, a cholinesterase inhibitor, may be used to reverse severe anticholinergic symptoms but should be administered with caution due to the risk of seizures and cardiac arrhythmias.
Patient education and counseling
Patients prescribed Atarax should be advised about the potential for sedation and cautioned against driving, operating heavy machinery, or engaging in hazardous activities until they know how the medication affects them. They should be counseled to avoid alcohol and other central nervous system depressants while taking hydroxyzine, as the combination can lead to dangerous levels of sedation and respiratory depression.
Patients should be instructed to take hydroxyzine exactly as prescribed and not to increase the dose or frequency without consulting their healthcare provider. Those using the medication for pruritus should be advised that it may take several days to achieve full therapeutic effect and that regular dosing is more effective than intermittent use.
Education about common side effects, particularly dry mouth and drowsiness, can help patients manage these effects. Simple measures such as sucking on sugar-free hard candy, chewing sugar-free gum, or using artificial saliva products can help alleviate dry mouth. Taking the medication at bedtime can help minimize daytime drowsiness when sedation is not desired.
Patients should be advised to seek medical attention if they experience symptoms such as fast or irregular heartbeat, difficulty urinating, severe dizziness, confusion, or signs of an allergic reaction including rash, swelling, or difficulty breathing. They should also inform all healthcare providers of their hydroxyzine use to avoid potentially harmful drug interactions.
Clinical efficacy in specific conditions
The efficacy of hydroxyzine in treating anxiety has been established through multiple clinical trials dating back several decades. In a landmark double-blind, placebo-controlled study of patients with generalized anxiety disorder, hydroxyzine at doses of 50 mg three times daily demonstrated significant reductions in Hamilton Anxiety Rating Scale scores compared to placebo, with improvements noted as early as the first week of treatment. The anxiolytic effect of hydroxyzine has been found to be comparable to that of benzodiazepines in some studies, though benzodiazepines typically have a faster onset of action. However, the advantage of hydroxyzine lies in its lack of dependence potential and the absence of withdrawal syndrome upon discontinuation, making it a safer option for longer-term management of anxiety.
In dermatological practice, hydroxyzine is considered a first-line therapy for acute urticaria and a valuable treatment option for chronic urticaria. Clinical studies have demonstrated that hydroxyzine 25 mg three to four times daily reduces the number, size, and duration of hives and provides substantial relief from pruritus. The antipruritic effect of hydroxyzine is particularly valuable in conditions such as atopic dermatitis, where the itch-scratch cycle can impair quality of life and disrupt sleep. By reducing the urge to scratch, hydroxyzine helps break this cycle and allows the skin to heal.
The antiemetic properties of hydroxyzine have been demonstrated in various clinical settings. In the postoperative period, hydroxyzine has been shown to reduce the incidence and severity of nausea and vomiting when used as part of a multimodal antiemetic regimen. The combination of hydroxyzine with other antiemetic agents such as ondansetron or dexamethasone has been found to provide more effective prophylaxis than any single agent alone. For motion sickness, hydroxyzine is moderately effective and may be considered as an alternative to first-line agents such as scopolamine or dimenhydrinate in patients who cannot tolerate these medications.
Pharmacogenomics and individual variability
Individual responses to hydroxyzine can vary due to genetic differences in drug-metabolizing enzymes, receptor sensitivity, and other pharmacokinetic and pharmacodynamic factors. The CYP2D6 enzyme, which plays a significant role in hydroxyzine metabolism, is genetically polymorphic, with approximately 7% to 10% of the Caucasian population classified as poor metabolizers. These individuals may experience higher plasma concentrations of hydroxyzine and prolonged drug effects, potentially increasing the risk of adverse effects such as excessive sedation and anticholinergic symptoms.
Similarly, genetic variations in the histamine H1 receptor gene (HRH1) and other receptor targets of hydroxyzine may influence individual sensitivity to the medication’s effects. While pharmacogenomic testing for antihistamine therapy is not currently part of routine clinical practice, awareness of the potential for genetically determined variability in drug response can help clinicians interpret unexpected responses to therapy and guide dose adjustment.
Age-related changes in drug metabolism and clearance also contribute to individual variability in hydroxyzine response. Elderly patients typically have reduced hepatic metabolism and renal clearance, leading to prolonged drug half-life and increased risk of accumulation with repeated dosing. This is particularly relevant for hydroxyzine, as its anticholinergic effects can exacerbate age-related cognitive decline and increase the risk of falls and fractures. The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults specifically cautions against the use of hydroxyzine in elderly patients due to its strong anticholinergic properties.
Formulations and pharmaceutical considerations
The pharmaceutical formulation of hydroxyzine can influence its clinical effects. The hydrochloride salt (Atarax) and the pamoate salt (Vistaril) have different pharmacokinetic properties, with the pamoate salt providing more prolonged absorption and potentially more sustained therapeutic effects. The clinical significance of these differences is modest, and both salt forms are considered therapeutically interchangeable for most indications.
The oral syrup formulation of hydroxyzine contains 10 mg per 5 mL and is sweetened and flavored to improve palatability for pediatric patients. Alcohol-free versions are available for patients who need to avoid alcohol for medical or personal reasons. The syrup formulation is particularly useful for precise dose titration in children and for patients who have difficulty swallowing tablets, but it should be measured carefully using an appropriate dosing device rather than household spoons to ensure accurate dosing.
Injectable hydroxyzine is formulated as a sterile solution for intramuscular administration and should never be administered intravenously, subcutaneously, or intra-arterially due to the risk of hemolysis, thrombosis, and tissue necrosis. The intramuscular injection provides rapid onset of action and is useful in emergency settings or when oral administration is not feasible. The injection site should be rotated to minimize discomfort and the risk of local reactions.
Long-term safety and monitoring considerations
For patients who require long-term hydroxyzine therapy, regular monitoring is recommended to assess ongoing efficacy, tolerability, and the development of any adverse effects. The anticholinergic effects of hydroxyzine are of particular concern with prolonged use, especially in elderly patients. Chronic anticholinergic exposure has been associated with an increased risk of cognitive decline and dementia in older adults, and the cumulative anticholinergic burden from multiple medications should be carefully considered.
Tolerance to the sedative effects of hydroxyzine often develops over several weeks of continued use, which is beneficial for patients who need the medication for its anxiolytic or antipruritic effects but wish to minimize daytime drowsiness. However, tolerance to the therapeutic effects of hydroxyzine does not typically develop to a clinically significant degree, and dose escalation is generally not required to maintain efficacy over time.
Abrupt discontinuation of hydroxyzine after prolonged use is generally well-tolerated and does not produce a withdrawal syndrome comparable to that seen with benzodiazepines or other central nervous system depressants. However, some patients may experience a temporary increase in anxiety, pruritus, or other symptoms that were being controlled by the medication, and gradual tapering may be considered in selected cases to minimize this rebound effect.
Special clinical scenarios and considerations
In patients with hepatic impairment, the metabolism of hydroxyzine may be reduced, leading to increased drug exposure and prolonged effects. Dose reduction and careful monitoring are essential in this population, and alternative medications with less hepatic metabolism may be preferred for patients with severe liver disease. Patients with renal impairment may also require dose adjustment, as renal clearance contributes to the elimination of hydroxyzine and its metabolites, particularly cetirizine.
Patients with certain medical conditions may require special consideration when using hydroxyzine. Those with narrow-angle glaucoma should use the medication with caution due to its anticholinergic effects on intraocular pressure. Patients with prostatic hyperplasia or a history of urinary retention may experience worsening of these conditions. Individuals with hyperthyroidism, cardiovascular disease, or hypertension should be monitored for potential cardiovascular effects, particularly tachycardia and arrhythmias.
The use of hydroxyzine in patients with a history of seizures or epilepsy is controversial, as the medication can lower the seizure threshold in susceptible individuals. While the risk is low at therapeutic doses, caution is advised, and alternative medications may be preferred for patients with poorly controlled seizure disorders.
Pediatric applications and dosing
In pediatric practice, hydroxyzine is commonly used for the treatment of pruritus associated with atopic dermatitis, urticaria, and other allergic conditions. The medication’s sedative properties can be particularly beneficial for children whose itching interferes with sleep, and the liquid formulation allows for accurate weight-based dosing. The recommended pediatric dose for pruritus is 0.5 mg to 1 mg per pound (1 mg to 2 mg per kilogram) of body weight per day, divided into three to four doses.
For preoperative sedation in children, hydroxyzine is often used in combination with other agents such as midazolam or ketamine to provide anxiety relief and reduce the requirements for anesthetic agents. The intramuscular route is typically used in this setting, with dosing based on body weight and the anticipated duration of the procedure.
Paradoxical reactions to hydroxyzine, characterized by increased agitation, hyperactivity, and irritability, are more common in children than in adults and may require discontinuation of the medication. Parents should be counseled about this possibility and advised to report any unusual behavioral changes to their healthcare provider promptly.
Hydroxyzine in palliative care and end-of-life settings
Hydroxyzine has important applications in palliative care, where it is valued for its multiple therapeutic effects in patients with advanced illness. The medication’s anxiolytic, antiemetic, antipruritic, and sedative properties make it useful for managing several common symptoms in terminally ill patients. For patients with terminal agitation or anxiety, hydroxyzine can provide calming effects without the respiratory depression associated with benzodiazepines or opioids.
Pruritus in palliative care populations, which can result from liver disease, kidney failure, opioid use, or the underlying malignancy, often responds well to hydroxyzine. The sedative effects of the medication can also help improve sleep quality in patients who experience discomfort or anxiety at night. The availability of oral, intramuscular, and rectal formulations provides flexibility in administration routes for patients who cannot take oral medications.
Comparison with other antihistamines
Hydroxyzine differs from second-generation antihistamines such as loratadine (Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra) primarily in its sedative profile and broader receptor activity. The newer antihistamines are designed to be non-sedating by limiting penetration into the central nervous system, making them more suitable for daytime use and for patients who need to remain alert. However, hydroxyzine’s central nervous system activity is therapeutically beneficial for anxiety disorders and for pruritus that disturbs sleep.
Compared to benzodiazepines used for anxiety, such as diazepam (Valium) and alprazolam (Xanax), hydroxyzine has a much lower potential for dependence, tolerance, and abuse. While benzodiazepines are more potent anxiolytics, they carry significant risks including physical dependence, withdrawal syndrome, and cognitive impairment. Hydroxyzine is generally considered safer for long-term use in anxiety management, though its anxiolytic effects are more modest.